/   Home   /   Newsroom   /   Research News

A Nanoplatform to Benefit Clinical Diagnosis and Chemotherapy of Cancer

Jul 04, 2017     Email"> PrintText Size

Collaborating with researchers from Anhui Medical University and Shanghai Jiao Tong University, a study team led by Professor WU Zhengyan in Institute of Technical Biology and Agriculture Engineering, Hefei Institutes of Physical Science, developed a yolk-like Fe3O4@Gd2O3 nanoplatform for targeted T1-T2 dual-mode MR imaging and chemotherapy of cancer.

The paper entitled A pH-Responsive Yolk-Like Nanoplatform for Tumor Targeted Dual-Mode Magnetic Resonance Imaging and Chemotherapy was published in ACS Nano. 

Incorporation of T1 and T2 contrast material in one nanosystem, which performs their respective MR contrast role and simultaneously serves as efficient drug delivery system, was potentially applicable in clinical diagnosis and chemotherapy of cancer.

However, inappropriate incorporation always encounters many issues, such as low contact area of T1 contrast material with water-proton, inappropriate distance between T2 contrast material and water molecule, and undesirable disturbance of T2 contrast material for T1 imaging.

Those issues seriously limits the T1 or T2 contrast effect. Therefore, it is of great importance to design new material with suitable nanostructure to avoid these issues.

In this work, researchers developed a yolk-like Fe3O4@Gd2O3 nanoplatform functionalized by PEG and folic acid (FA), which could efficiently exert their tumor targeted T1-T2 dual-mode MR imaging and drug delivery role.

Then cisplatin could be efficiently loaded into this nanoplatform (112 mg/g) and showed pH-responsive release behavior.

In addition, the nanoplatform could be effectively internalized by HeLa cells with time- and dosage-dependence.

Importantly, the FA receptor mediated nanoplatform displayed excellent T1-T2  dual mode MR contrast enhancement and anticancer activity both in vitro and in vivo. And no apparent toxicity for vital organs was observed under systemic delivery of the nanoplatform in vivo.

This work has a potential application in design of multifunctional nanotheranostic as dual-mode MR contrast agent and drug delivery system.

This research was supported by the National Natural Science Foundation of China, the Key Program of Chinese Academy of Sciences, and the Youth Innovation Promotion Association of Chinese Academy of Sciences.

 

Schematic illustration of the fabrication process, systemic delivery of FA-PYFGN-CDDP in vivo, and corresponding diagnosis and therapy for tumor. (Image by SUN Xiao) 

Attachment:

(Editor: ZHANG Nannan)

Related Articles

cancer;medical imaging;ultrasound;breast cancer;mammogram;breast screening;breast cancer screening

China Enlists AI to Diagnose Breast Cancer

Jul 10, 2017

Doctors in China will soon read patient breast scans with the help of machines. The National Clinical Research Center for Cancer (NCRCC) said Friday that it has signed a deal with the Institute of Computing Technology under the Chinese Academy of Sciences (CAS) to use art...

cancer;cancer detection;3D imaging

China-Australia Research Team Develops New Software for Early Cancer Detection

Jun 01, 2017

A team of Australian and Chinese scientists have developed sophisticated new software which could play a key role in the early detection of cancer. Australia's Commonwealth Scientific and Industrial Research Organisation (CSIRO) released a statement on Wednesday saying th...

Contact Us

Copyright © 2002 - 2017 Chinese Academy of Sciences